FIT Biotech Oy
Company release 3.1.2019 at 15:30 EET
Changes in FIT Biotech’s management
Kalevi Reijonen, FIT Biotech Oy’s (“Company”, FITBIO: FN Finland) Chief Medical Officer and a member of the Management Team, will retire in January 2019.
CEO Erkki Pekkarinen comments:
“I want to warmly thank Kalevi for his valuable contribution to FIT Biotech and wish him all the best in his retirement. Kalevi has had an important role in FIT Biotech’s development into international biotechnology company first as a CEO (2003-2015) and then as a CMO of the company.”
Company has initiated a recruitment process for a new Medical Manager.
FIT Biotech Oy
Board of Directors
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies its GTU® technology in its development projects, which at the time include gene-based treatments, genetic vaccines and research collaboration. Application areas include cancer (gene therapy) and infectious diseases such as HIV.
FIT Biotech K-shares are listed on the First North Finland market maintained by Nasdaq Helsinki Ltd.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
www.fitbiotech.com
